Changes in joint cartilage aggrecan after knee injury and in osteoarthritis.

OBJECTIVE To determine the concentrations of aggrecan fragments in synovial fluid from patients with knee joint injury, osteoarthritis (OA), or acute pyrophosphate arthritis (PPA; pseudogout), and to test their relative reactivity with the 846 epitope, a putative marker of cartilage aggrecan synthesis. METHODS Samples of knee joint fluid from 385 patients and 9 healthy-knee volunteers were obtained in a cross-sectional study. Study groups were acute PPA/ pseudogout (n = 60), anterior cruciate ligament (ACL) rupture (n = 159), meniscus lesion (n = 129), and primary knee OA (n = 37). The 846 epitope on aggrecan was assayed by competitive solution-phase radioimmunoassay. Aggrecan fragments were assayed by enzyme-linked immunosorbent assay using a monoclonal antibody (1-F21). Cartilage oligomeric matrix protein (COMP), C-propeptide of type II collagen (CPII), bone sialoprotein, matrix metalloproteinases 1 and 3, and tissue inhibitor of metalloproteinases 1 were previously quantified by immunoassays. RESULTS Reactivity of the 846 epitope was increased in all study groups compared with the reference group, and was highest in patients with primary OA. The median levels (in microg fetal aggrecan equivalents/ml) of the epitope were 0.28 (range 0.24-0.47) in the reference group, 0.48 (range 0.26-1.32) in PPA/pseudogout, 0.61 (range 0.12-2.87) in ACL rupture, 0.53 (range 0.22-3.02) in meniscus lesion, and 0.68 (range 0.31-4.31) in primary OA. The 846 epitope reactivity per microg aggrecan fragments in the joint fluid was higher in late-stage OA than in early-stage OA. Epitope 846 reactivity correlated positively with several markers of matrix turnover, particularly with COMP (r(s) = 0.421) and CPII (r(s) = 0.307). CONCLUSION The observed differences in 846 epitope reactivity in synovial fluid, and its concentration in relation to aggrecan and other markers of matrix turnover, were consistent with marked ongoing changes in aggrecan turnover after joint injury and in the development of OA. OA is thus a disease characterized by dynamic changes in tissue macromolecule turnover, which is reflected by measurable changes in aggrecan epitopes in the synovial fluid.

[1]  B. Månsson,et al.  Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. , 1995, The Journal of clinical investigation.

[2]  L. Lohmander,et al.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. , 1993, Arthritis and rheumatism.

[3]  M. Aebi,et al.  The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. , 1996, The Journal of clinical investigation.

[4]  H. Roos,et al.  Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis , 1997, Annals of the rheumatic diseases.

[5]  T. Aigner,et al.  Independent expression of fibril-forming collagens I, II, and III in chondrocytes of human osteoarthritic cartilage. , 1993, The Journal of clinical investigation.

[6]  Mauro Alini,et al.  9 – Cellular Biology of Cartilage Degradation , 1995 .

[7]  H. Roos,et al.  Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. , 1996, The Journal of rheumatology.

[8]  H. Roos,et al.  Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. , 1993, The Journal of rheumatology.

[9]  J. E. Bassett,et al.  Cartilage matrix molecules in serum and synovial fluid. , 1995, Current opinion in rheumatology.

[10]  C. Rorabeck,et al.  Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.

[11]  H. Mankin,et al.  Collagen synthesis in normal and osteoarthritic human cartilage. , 1977, The Journal of clinical investigation.

[12]  D. Heinegård,et al.  Matrix proteins: potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. , 1995, The Journal of rheumatology. Supplement.

[13]  C. Rorabeck,et al.  Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. , 1995, The Journal of clinical investigation.

[14]  K. Brandt,et al.  Accelerated clearance of albumin from the osteoarthritic knee: implications for interpretation of concentrations of "cartilage markers" in synovial fluid. , 1996, The Journal of rheumatology.

[15]  D. Heinegård,et al.  Increased concentrations of bone sialoprotein in joint fluid after knee injury. , 1996, Annals of the rheumatic diseases.

[16]  P. Roughley,et al.  Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. , 1986, The Biochemical journal.

[17]  A. Poole,et al.  Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. , 1992, The Journal of clinical investigation.

[18]  A. Ratcliffe,et al.  Changes in proteoglycan turnover in experimental canine osteoarthritic cartilage. , 1992, Matrix.

[19]  D. Heinegård,et al.  Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. , 1992, Arthritis and rheumatism.

[20]  W. Nelp,et al.  Protein traffic in human synovial effusions. , 1987, Arthritis and rheumatism.

[21]  H. Muir,et al.  Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental osteoarthritis , 1984, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  M. Bayliss,et al.  Monoclonal antibodies that detect biochemical markers of arthritis in humans. , 1995, Arthritis and rheumatism.

[23]  H J Mankin,et al.  Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. , 1970, The Journal of bone and joint surgery. American volume.

[24]  S. Ahlback,et al.  Osteoarthrosis of the knee. A radiographic investigation. , 1968 .

[25]  P. Dieppe,et al.  Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. , 1994, The Journal of clinical investigation.

[26]  L. Lohmander,et al.  The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. , 1993, Arthritis and rheumatism.

[27]  H. Roos,et al.  A longitudinal study of cartilage matrix metabolism in patients with cruciate ligament rupture--synovial fluid concentrations of aggrecan fragments, stromelysin-1 and tissue inhibitor of metalloproteinase-1. , 1994, British journal of rheumatology.

[28]  H. Møller,et al.  ELISA for the core protein of the cartilage large aggregating proteoglycan, aggrecan: comparison with the concentrations of immunogenic keratan sulphate in synovial fluid, serum and urine. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[29]  J. Matyas,et al.  Discoordinate gene expression of aggrecan and type II collagen in experimental osteoarthritis. , 1995, Arthritis and rheumatism.

[30]  H. Muir,et al.  Structure of newly synthesised (35S)‐proteoglycans and (35s)‐proteoglycan turnover products of cartilage explant cultures from dogs with experimental osteoarthritis , 1985, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[31]  E. Thonar,et al.  Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise. , 1995, Osteoarthritis and cartilage.

[32]  H. Muir,et al.  In vivo and in vitro stimulation of chondrocyte biosynthetic activity in early experimental osteoarthritis. , 1984, Arthritis and rheumatism.

[33]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[34]  R. Kotz,et al.  Muscle function after endoprosthetic replacement of the proximal tibia. Different techniques for extensor reconstruction in 17 tumor patients. , 1995, Acta orthopaedica Scandinavica.

[35]  A. Poole.  Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? , 1994, Annals of the rheumatic diseases.

[36]  S. Bjornsson.  Simultaneous preparation and quantitation of proteoglycans by precipitation with Alcian blue , 1993 .

[37]  L Ryd,et al.  Proteoglycan fragments in joint fluid. Influence of arthrosis and inflammation. , 1992, Acta orthopaedica Scandinavica.

[38]  H. Dorfman,et al.  Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. , 1971, The Journal of bone and joint surgery. American volume.

[39]  R. E. Outerbridge.  THE ETIOLOGY OF CHONDROMALACIA PATELLAE , 1961 .

[40]  J. Dingle,et al.  Clearance of proteoglycan from joint cavities. , 1987, Annals of the rheumatic diseases.

[41]  R. Midura,et al.  Chemical and Immunological Assay of the Nonreducing Terminal Residues of Chondroitin Sulfate from Human Aggrecan* , 1997, The Journal of Biological Chemistry.

[42]  J. Fairclough,et al.  Changes in glycosaminoglycan epitope levels in knee joint fluid following injury. , 1995, Arthritis and rheumatism.

[43]  Lohmander Ls,et al.  Articular cartilage and osteoarthrosis. The role of molecular markers to monitor breakdown, repair and disease. , 1994 .

[44]  D. Heinegård,et al.  Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. , 1994, Annals of the rheumatic diseases.

[45]  D. Eyre,et al.  Biosynthesis of collagen and other matrix proteins by articular cartilage in experimental osteoarthrosis. , 1980, The Biochemical journal.

[46]  J. Glowacki,et al.  Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. , 1994, The Journal of clinical investigation.